The Mosaic Company MOS

Key data

The business

Mosaic digs two things out of the ground and sells them to farmers: potash, mostly from mines in Saskatchewan and New Mexico, and phosphate, from Florida and Louisiana, finished into the crop nutrients that go on corn, soybeans and sugarcane. A third arm, its Brazil distribution business, blends and resells across South America. Thirteen thousand employees, customers in more than 40 countries, and a price it does not set: potash and phosphate are commodities quoted by the ton, and Mosaic is a price taker on both. The moat, such as it is, is cost and geology, low-cost potash reserves and integrated phosphate rock that are hard to replicate, not a brand or a switching cost. When nutrient prices run ahead of mining and processing costs, Mosaic mints money, FY2022 threw off $10.06 a share. When input costs, sulfur and ammonia for phosphate, run ahead of selling prices, the same tonnage bleeds. That is the whole cycle, and right now the cycle is against it.

The numbers

The turn is stark. Three quarters of solid profit through Q3 2025 gave way to three straight losses, and the cause is not volume, which held or grew. It is margin. Adjusted for the asset write-downs that drove the GAAP red ink, Mosaic still earned a thin $0.13 a share in Q2 2026, a hair above the $0.12 the Street penciled in, but that is a company running near breakeven, not the earner of a year ago.

Read across a decade and the shape is a commodity, not a compounder: $19.1 billion of revenue at the 2022 peak, $11.1 billion in the 2024 trough, and earnings that swing from ten dollars to fifty-five cents a share and back. Mid-cycle, this business earns perhaps $2.50 to $3.00 a share, which puts the price near nine or ten times a normal year, not demanding, not a giveaway. The cleaner tell is book value: the stock changes hands at about 0.72 times the carrying value of its own mines and plants, below the cost of the assets, which is where cyclicals sit at the bottom and rarely at the top.

There is the leak. Volumes rose, phosphate shipments up 10% for the half, and gross margin still halved, as the phosphate segment's margin fell to a $1.1 million loss for the six months from $270.3 million a year earlier. Only days have passed since this name was last examined and no new print has landed, so that collapse is unbroken and remains the single thing that has to turn. What this memo believes that the tape does not: the phosphate squeeze is an input-cost event, not a demand event, and the print that settles it is the phosphate segment margin turning positive again, likely in the Q3 report this November.

Management

Bruce Bodine took the top job in March 2024 and has run straight into the down-leg. The capital record tells the honest story: buybacks went from $1.67 billion in 2022 to $756 million, then $235 million, then zero in 2025, cut as earnings fell rather than pressed when the stock got cheap, which is prudent but not the countercyclical nerve owners hope for. In August the company was busy in the debt market, tender offers and a make-whole redemption to refinance rather than pay down, sensible housekeeping at a trough. Insider activity is noise: one small officer purchase of $17,488 last November, one $508,760 sale in August with plan status not disclosed, nothing that reads as conviction either way.

How it fails or surprises you

Potash snaps back (right tail). Potash is a three-hand oligopoly with Russian and Belarusian tons still constrained, and Mosaic's are among the lowest-cost in the world. A $40 to $50 per-ton move in realized potash price, which the market pays nothing for today, drops almost straight to margin. First seen in the potash segment realized price in the Q3 disclosure.

Phosphate costs stay high. This is the fact the bullish read explains least. If sulfur and ammonia hold near current levels into 2027, phosphate keeps losing money on rising volume, and the "input-cost event, not demand event" thesis is simply wrong. The tell is a second straight quarter of negative phosphate segment margin despite flat or higher shipments.

Leverage bites at the trough. Net debt sits near 3.3 times a normal year's cash earnings, free cash flow ran about negative $884 million over the last year on $1.4 billion of annual capex, and cash is $294 million. Another year of trough pricing pressures the dividend and the balance sheet both. Watch operating cash flow against capex in the next two prints.

Closing thoughts

The market has already made up its mind on the near term: 0.72 times book is trough pricing, and it is roughly right that today's Mosaic earns close to nothing. The edge is not in the quarter, it is in what a specific print converts into. If phosphate segment margin turns positive this November and potash realized price firms, the below-book cyclical re-rates on a multi-year view; if the November print shows volumes up and margin still negative, the input-cost thesis is broken and this is a value trap with leverage. An ambiguous print, margin near zero, means you wait for Q4. The fatter tail on a patient hold is up, because you are buying assets below their carrying value at the bottom of a cycle in a commodity nobody can quickly add supply to, but the left tail is real, and it is leverage meeting a longer trough.

The bet is still that the prices farmers pay for crop nutrients, the potash and phosphate Mosaic mines and ships, stay high enough to cover the cost of making them, and that the sulfur and ammonia that go into phosphate get cheaper. What breaks it is a second quarter of negative phosphate margin on higher volume; the one pair of numbers that tells you first is phosphate shipments against phosphate segment gross margin in the November report. Below book at the trough is a place to start looking, not a verdict.